AstraZeneca said on Friday that a new study showed its dry powder inhaler Symbicort (budesonide and formoterol) was superior to either inhaled corticosteroids or long acting beta-agonists given as monotherapy in COPD.
Anders Ekblom, Vice President, Respiratory Therapy Area, AstraZeneca, said in a statement the findings provided “robust support” for the company’s application earlier this year to extend the drug’s asthma label to COPD.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!